Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

CONCLUSIONS: This analysis supports a switch from BSA-based to fixed dosing, without dose modification for mild/moderate renal impairment or age, in future adult studies of ixazomib, simplifying dosing guidance and clinical development. PMID: 25377318 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25377318?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - November 6, 2014 Category: Cancer & Oncology Authors: Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K Tags: Br J Clin Pharmacol Source Type: research

More News: Cancer & Oncology | Lymphoma | Myeloma | Study